Alzumab L 100mg Injection contains an active component as Itolizumab. It is a monoclonal antibody used to treat certain autoimmune conditions, particularly moderate to severe psoriasis and rheumatoid arthritis. Monoclonal antibodies are synthetic proteins designed to mimic the immune system's ability to target specific substances in the body. This medication was originally developed in Cuba and has been approved for moderate to severe plaque psoriasis. It has shown promising results in studies for rheumatoid arthritis as well. This medication has generally shown good tolerability in clinical trials. Common side effects are usually mild to moderate, including infusion-related reactions, headache, dizziness, and mild gastrointestinal symptoms. Serious adverse events are relatively rare.

Individuals with known hypersensitivity or severe allergic reactions to Alzumab L 100mg Injection or any of its components should avoid its use. This medication may impact the immune system, increasing the risk of infections. Patients with active infections may need to have their condition managed and the infection resolved before starting treatment. Live vaccines should be avoided during treatment since they may interfere with effectiveness. Patients should consult their healthcare provider about appropriate vaccination schedules. Individuals with certain pre-existing conditions, such as immunosuppression or a history of severe infections, may require caution due to the potential risk of further immunosuppression.

Alzumab L 100mg Injection is used to treat the following:

• Chronic plaque psoriasis
• Rheumatoid arthritis

Alzumab L 100mg Injection, a monoclonal antibody drug, is therapeutic by targeting CD6, a cell surface protein found on T cells. By binding to CD6, this medication modulates the immune response, effectively controlling the activity of T cells that play a crucial role in various autoimmune disorders. In conditions like moderate to severe psoriasis and rheumatoid arthritis, where the immune system is overactive and causes inflammation and tissue damage, it helps to regulate the immune response, reducing inflammation and mitigating symptoms such as skin lesions in psoriasis and joint inflammation in rheumatoid arthritis.

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Alzumab L 100mg Injection, reducing effectiveness by causing undesirable side effects. 

• Store at refrigerator temperature between 2°C to 8°C (36°F to 46°F).
• Keep away from moisture, heat, and light.
• It should not be frozen.
• Keep away from children and pets.

The usage of Alzumab L 100mg Injection typically involves intravenous (IV) injection under the supervision of a healthcare professional. The prescribing doctor will determine the dosage and frequency of administration based on the specific medical condition being treated and the patient's individual response to the medication. This medication should only be administered by trained healthcare personnel in a clinical setting, and patients should follow their doctor's instructions carefully. 

Alzumab L 100mg Injection causes some side effects like all medications, although not everyone will experience them. 

Serious:

• Severe allergic reactions, including rash, itching, swelling, severe dizziness, or difficulty breathing
• Infections
• Neurological events (seizures)
• Liver problems
• Anemia (decreased red blood cell)
• Decreased white blood cell

Common:

• Headache
• Dizziness
• Nausea or vomiting
• Abdominal discomfort
• Diarrhea
• Fatigue
• Rash or itching at the injection site
• Infusion-related reactions (e.g., fever, chills, flushing)

Advice regarding Alzumab L 100mg Injection is to always consult with a healthcare professional before starting or making any changes to your medication regimen. They can assess your medical history, evaluate potential risks and benefits, provide personalized guidance, and monitor your progress throughout treatment. Additionally, closely follow your healthcare provider's instructions and recommendations, promptly report any unusual or concerning symptoms, and communicate openly about any concerns or questions you may have. This medication can increase the risk of blood clotting. This is particularly relevant in individuals with a history of thromboembolic events or at risk of developing blood clots. Close monitoring for signs of clotting disorders or complications is necessary during treatment. Precautions should be taken when using this medication in patients with liver or kidney impairment, as dosage adjustments or special monitoring may be required. Pregnant and breastfeeding individuals should consult with healthcare professionals before using this medication. Your healthcare professional is the best resource for ensuring safe and effective medication use.

1. Biocon Ltd, [Issued on Jan 2013] [ Accessed on 23rd July 2023], https://www.biocon.com/docs/prescribing_information/immunotherapy/alzumab_pi.pdf
2. Ankita Srivastava; Itolizumab in Psoriasis; Indian Journal of Dermatology; [Published on Aug 2017]; [Accessed on 23/07/2023]; https://www.ncbi.nlm.nih.gov/pubmed/28794555